Partnering with Takeda

At Takeda, partnerships are at the heart of what we do. Almost one third* of our revenues come from partnerships and strategic acquisitions, and that will grow to over 50 percent by 2015*. We have significant experience in developing mutually beneficial discovery, development and commercial relationships. Our dedicated alliance management function fosters strong relationships throughout the product life cycle, from early development to late stage. Our teams apply Takeda's core values of perseverance, honesty and fairness to every collaboration.

Takeda has always valued innovation. We have a history of acquiring companies with strong scientific platforms and expertise – Syrxx (now Takeda California), Paradigm Pharmaceuticals (now Takeda Cambridge and Takeda Singapore) and Millennium Pharmaceuticals (now Millennium: The Takeda Oncology Company). We invest in them, allowing them to flourish and achieve their full potential.

Takeda has a proven track record in Research and Development, having brought leading treatments to market for diabetes, gastrointestinal disorders and cancer. We spend over 20 percent of our revenues on R&D, one of the highest investments in the industry.

We also have a global and highly respected expertise in product commercialization in our core therapeutic areas. Our recent acquisition and integration of Nycomed has not only strengthened our pan-European platform, but also expanded our sales channels into emerging markets, offering integrated global product development.

Our highly efficient and adaptable worldwide manufacturing network has the ability to produce diverse products applying a wide range of technologies, from API to production and packaging of solid, semi-solid, liquid and injectable pharmaceuticals. With the know-how and the capacity of our manufacturing plants throughout the world, we are close to our customers in far-reaching markets.

Collectively these capabilities mean that, with you, we are uniquely positioned to develop new products and to commercialize existing products in markets around the world. We can strive together to achieve the best outcomes for our patients.

*including Nycomed acquried in 2011

What Takeda offers to partners

Background to Takeda

12^th largest pharmaceutical company globally

As of end of March 2012

Market and geographic focus

Takeda develops its product for multiple markets and commercializes them around the globe. We are present in Japan, the United States, Europe, Latin America, Africa, the Middle East, and the Asia Pacific Region. Our local regulatory expertise offers advantages in both mature and emerging markets, and our global manufacturing capabilities allow us to fulfil both global and local market demands.

Our global reach

We are proud of our global footprint, and offer you access to both our state-of-the-art R&D facilities around the world, and to our manufacturing and supply chain networks.

Global Research & Development Network - Our Research facilities are headquartered in Japan (Shonan) and our global Development functions are headquartered in the United States (Deerfield, IL). Takeda's R&D network is broad, extending to Takeda California and Cambridge, Massachusetts (Millennium) in the United States, and locations in the UK (Cambridge and London, England), Europe (Roskilde, Denmark), Asia (China and Singapore) and Japan.

Global Manufacturing Capabilities - Our global manufacturing network includes plants around the world, ensuring that we are always close to our customers. Our highly efficient global supply chain network has been established to meet both global and local needs, can be readily tailored to a diverse portfolio and can adapt to volatile demand in emerging markets.

Takeda Pipeline

• Our Product Pipeline